Heron Therapeutics’ patent of Cinvanti found valid by Delaware District Court

Heron Therapeutics (HRTX) announced that the U.S. District Court for the District of Delaware ruled in Heron’s favor in the Company’s patent litigation against Fresenius Kabi USA with respect to CINVANTI, or aprepitant, injectable emulsion. The district court found that Heron’s U.S. Patent Nos. 9,561,229 and 9,974,794, which expire in 2035, are valid and would be infringed by Fresenius’ proposed generic product. The district court decision concludes the litigation initiated in July 2022 in response to Fresenius’ submission of an Abbreviated New Drug Application with the FDA seeking approval of a generic version of CINVANTI. As a result of the decision, Heron will seek an order from the Court prohibiting Fresenius from launching its generic CINVANTI until after the expiration of the patents in 2035. This decision is subject to appeal.